Evidence map›Paper›PMID 39107888›Full record

ArticleBioinformatics (Oxford, England)2024

Locuaz: an in silico platform for protein binders optimization.

German P Barletta, Rika Tandiana, Miguel Soler, Sara Fortuna, Walter Rocchia

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

German P BarlettaCONCEPT, Istituto Italiano di Tecnologia, Via Enrico Melen, 83 Genova Liguria 16152, Italy.ORCID 0000-0002-0806-0812
Rika TandianaCONCEPT, Istituto Italiano di Tecnologia, Via Enrico Melen, 83 Genova Liguria 16152, Italy.
Miguel SolerCONCEPT, Istituto Italiano di Tecnologia, Via Enrico Melen, 83 Genova Liguria 16152, Italy.ORCID 0000-0002-5780-9949
Sara FortunaCONCEPT, Istituto Italiano di Tecnologia, Via Enrico Melen, 83 Genova Liguria 16152, Italy.
Walter RocchiaCONCEPT, Istituto Italiano di Tecnologia, Via Enrico Melen, 83 Genova Liguria 16152, Italy.ORCID 0000-0003-2480-7151

Funding

AIRC 24589
6 · The paper itself

Abstract

motivationEngineering high-affinity binders targeting specific antigenic determinants remains a challenging and often daunting task, requiring extensive experimental screening. Computational methods have the potential to accelerate this process, reducing costs and time, but only if they demonstrate broad applicability and efficiency in exploring mutations, evaluating affinity, and pruning unproductive mutation paths.

resultsIn response to these challenges, we introduce a new computational platform for optimizing protein binders towards their targets. The platform is organized as a series of modules, performing mutation selection and application, molecular dynamics simulations to sample conformations around interaction poses, and mutation prioritization using suitable scoring functions. Notably, the platform supports parallel exploration of different mutation streams, enabling in silico high-throughput screening on High Performance Computing (HPC) systems. Furthermore, the platform is highly customizable, allowing users to implement their own protocols. AVAILABILITY AND IMPLEMENTATION: The source code is available at https://github.com/pgbarletta/locuaz and documentation is at https://locuaz.readthedocs.io/. The data underlying this article are available at https://github.com/pgbarletta/suppl_info_locuaz.

Indexed as

ProteinsSoftwareComputational BiologyComputer SimulationMolecular Dynamics SimulationMutationProtein BindingProtein EngineeringProteins

Identifiers

PMID39107888
PMCPMC11324344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.